SEHK:9969Biotechs
Assessing InnoCare Pharma (SEHK:9969) Valuation As Its Autoimmune Pipeline Advances Through Key Trial Milestones
InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications.
See our latest analysis for InnoCare Pharma.
Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...